Maxx Chatsko has a pretty good review on the M F today
worth reading if you are a long. There is plenty of excitement/action coming up for rgen. The opus colums, PFE collaborative pipeline and ofcourse the potential for snapping up a v good acquisition. All this in addition to the steadily improving core product business.
Smith on stocks Nov 24 was a far superior detailed analysis - Chatsko mentioned everything we already knew
from months ago.......in any event this next year should be very interesting.....imagine loss of royalties are already factored BUT with a biotech any bad news could lose a buck or two i.e. poor news on partnering or 1068 or worse than expected sales due to manufacturing unforeseen problems....upside use of cash and or greater top line results / opus growth.